Recalcitrant pyoderma gangrenosum treated with thalidomide.
Pyoderma gangrenosum is a painful, noninfectious, ulcerating skin disorder often associated with systemic disease. Thalidomide has been used to treat many inflammatory dermatologic conditions and has been reintroduced in the United States to treat immune-modulated diseases such as pyoderma gangrenosum. The patient described, a 47-year-old man, had histologically confirmed pyoderma gangrenosum that did not respond to treatment with several courses of methylprednisolone. The ulcer healed with 10 weeks of oral thalidomide administration.
Federman
G L
GL
Department of Dermatology, Yale University School of Medicine, New Haven, CT 06516, USA.
Federman
D G
DG
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000188:drug therapy*; D012008:Recurrence; D013792:Thalidomide / Q000627:therapeutic use*; D017211:Treatment Failure; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D013792:Thalidomide; D008775:Methylprednisolone